Nurse Practitioner, Community Health · Binghamton, NY
NPI
1811665789
Since 2021
Specialty
Nurse Practitioner, Community Health
Code 363LC1500X
Group practices
2
Medicare group memberships
Hospitals
1
Hospital affiliations
93 Pennsylvania Ave
Binghamton, NY, 13903
Phone (607) 763-6092
Groups this clinician bills Medicare through
Medicare paid, 2024
$22K
517 services
Medicare patients, 2024
188
Average age 70
Drug cost, 2024
$3.8M
5,591 prescriptions
Company payments, 2025
$418
From 16 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Danielle Mejias was code 99214 (office e&m - established), 334 times for 167 patients. In total Danielle Mejias billed 517 services in 7 codes, and Medicare paid $22K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-09-03.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 334 | 167 | $52.77 | $18K |
| 95251 Test - Miscellaneous | Office | 95 | 48 | $20.08 | $1,908 |
| 99213 Office E&M - Established | Office | 60 | 46 | $38.74 | $2,324 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 11 | 11 | $9.75 | $107 |
By year: 2022 $19K for 374 services; 2023 $24K for 518 services; 2024 $22K for 517 services.
Medicare prescription drug claims, 2024
In 2024, the drug Danielle Mejias prescribed most often to Medicare patients was Mounjaro (Tirzepatide), with 495 prescriptions and refills. In total Danielle Mejias wrote 5,591 Medicare prescriptions that cost $3.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Mounjaro Tirzepatide | 495 | 562 | 97 | $588K |
| Ozempic Semaglutide | 434 | 947 | 133 | $895K |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 377 | 954 | 139 | $70K |
| Jardiance Empagliflozin | 325 | 818 | 98 | $464K |
| Metformin Hcl Generic | 255 | 672 | 95 | $2,004 |
| Novolog Flexpen Insulin Aspart | 211 | 431 | 77 | $74K |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 203 | 464 | 78 | $21K |
| Trulicity Dulaglutide | 189 | 324 | 46 | $324K |
| Ultra-Fine Nano Pen Needle Pen Needle, Diabetic | 187 | 423 | 70 | $18K |
| Novolog Mix 70-30 Flexpen Insulin Aspart Prot/Insuln Asp | 158 | 334 | 44 | $57K |
| Tresiba Flextouch U-100 Insulin Degludec | 138 | 362 | 49 | $153K |
| Humalog Mix 75-25 Kwikpen Insulin Lispro Protamin/Lispro | 136 | 265 | 46 | $58K |
| Metformin Hcl Er Metformin Hcl | 125 | 340 | 47 | $2,232 |
| Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog | 124 | 264 | 34 | $57K |
| Levothyroxine Sodium Generic | 110 | 255 | 41 | $1,337 |
Brand drugs: 3,546 claims; generic drugs: 1,185 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Danielle Mejias $418 ($418 in general payments such as food, travel and fees) from 16 companies. The largest payer was Lilly USA, LLC with $45.58.
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC LLY | 2 | $45.58 |
| Sequel Med Tech, LLC | 2 | $41.44 |
| Inspire Medical Systems, Inc. INSP | 2 | $40.59 |
| Dexcom, Inc. DXCM | 2 | $39.06 |
| Antares Pharma, Inc. | 2 | $34.54 |
| Radius Health, Inc. | 1 | $33.05 |
| Abbott Laboratories ABT | 1 | $24.14 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $22.26 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 1 | $21.31 |
| Corcept Therapeutics CORT | 1 | $19.83 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.